

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 10147

REPLY TO QUESTION 1A OF DSA CAMERON STATION MESSAGE - R271751Z FEB 74

At one point in Mr. Feinberg's 8 November speech a list of Meprobamate suppliers as taken from the Blue Book was presented on the screen. The narrative indicated that ten of the firms were rejected as a result of plant visits. There was no indication that these rejections were for Meprobamate Tablets alone. In fact not all of these firms are bidders for Meprobamate Tablets.

Surveys are listed below along with the dates of rejection and notification to FDA. A summary of the major deficiencies is attached:

<u>Company</u>	<u>Product</u>	<u>Date of Rejection</u>	<u>Date FDA Advised</u>
Barr Labs.	Diphenhydramine HCl	July 73	25 July 73 ✓
	Pyridoxine HCl		
	Meprobamate	October 73	25 October 73
Kirkman Labs.	Bismuth Subcarbonate	July 73	12 July 73
ICN (Strong Cobb Arner)	Meprobamate	June 73	June 73 ✓
Zenith	Meprobamate	June 73	29 June 73 ✓
American Quinine (Natcon)(Napp)	Propoxyphene HCl	April 73	3 May 73
Bell Pharmacal Corp.	No Specific Product	February 73	February 73
Stanlabs.	Codeine Sulfate	May 68	September 68
	Calcium Lactate		
Bowman	Sodium Fluoride	March 67	March 67
Fellows (Kapeco)	Sodium Aminosalicylate	July 66	July 66
Richlyn	No Specific Product	February 66	April 66